Northwest Quadrant Wealth Management LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Northwest Quadrant Wealth Management LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 5.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,203 shares of the company’s stock after purchasing an additional 315 shares during the period. Johnson & Johnson accounts for about 0.4% of Northwest Quadrant Wealth Management LLC’s portfolio, making the stock its 17th largest position. Northwest Quadrant Wealth Management LLC’s holdings in Johnson & Johnson were worth $863,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Bowen Hanes & Co. Inc. lifted its stake in shares of Johnson & Johnson by 11.5% in the 4th quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock valued at $52,868,000 after purchasing an additional 37,290 shares during the period. Chelsea Counsel Co. lifted its stake in shares of Johnson & Johnson by 3.9% in the 4th quarter. Chelsea Counsel Co. now owns 45,344 shares of the company’s stock valued at $6,614,000 after purchasing an additional 1,693 shares during the period. Sector Gamma AS lifted its stake in shares of Johnson & Johnson by 0.3% in the 1st quarter. Sector Gamma AS now owns 117,532 shares of the company’s stock valued at $15,412,000 after purchasing an additional 303 shares during the period. Tradewinds Capital Management LLC lifted its stake in shares of Johnson & Johnson by 1.3% in the 1st quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock valued at $997,000 after purchasing an additional 101 shares during the period. Finally, Pennsylvania Trust Co lifted its stake in shares of Johnson & Johnson by 1.3% in the 1st quarter. Pennsylvania Trust Co now owns 409,496 shares of the company’s stock valued at $53,698,000 after purchasing an additional 5,413 shares during the period. Institutional investors own 68.51% of the company’s stock.

Several equities research analysts recently commented on the stock. Credit Suisse Group reissued a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a report on Tuesday, April 28th. Raymond James boosted their price target on shares of Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and cut their price target for the stock from $163.00 to $160.00 in a report on Tuesday, April 28th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $168.00 target price on shares of Johnson & Johnson in a report on Tuesday, April 28th. Finally, Argus reaffirmed a “buy” rating and set a $155.00 target price (down previously from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $162.93.

Johnson & Johnson stock traded down $2.03 during midday trading on Thursday, reaching $141.25. The company’s stock had a trading volume of 1,524,309 shares, compared to its average volume of 7,245,217. The firm has a market capitalization of $377.46 billion, a PE ratio of 18.95, a P/E/G ratio of 3.11 and a beta of 0.69. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.05 and a current ratio of 1.31. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The stock’s 50 day simple moving average is $143.95 and its 200 day simple moving average is $143.96.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The business’s quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.10 EPS. Equities analysts predict that Johnson & Johnson will post 7.7 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.86%. The ex-dividend date was Friday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is the 52-week high/low?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.